EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Clinical and experimental treatment of residual immune activation in people living with HIV

Krystelle Nganou-Makamdop iD

Clinical and Experimental Immunology · 21.01.2025 · 219 (1)

DOI: 10.1093/cei/uxaf023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 17.04.2025. Verfasst von Krystelle Nganou-Makamdop. Beteiligte Einrichtung: Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: HIV Infections, Lymphocyte Activation, Anti-Inflammatory Agents, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Potent inflammatory responses stemming from innate and T cell activation are initiated during acute human immunodeficiency virus infection. Suppression of the virus replication by antiretroviral therapy reduces but does not normalize immune activation. By now, it is clear that residual immune activation can persist even after years of antiretroviral therapy and associates with increased risks for co-morbidities, thereby raising interest for strategies that can resolve the residual immune activation in people with human immunodeficiency virus on antiretrovirals. This brief review reports the human studies with various drugs with anti-inflammatory properties and their effects on measures of systemic immune activation on people with human immunodeficiency virus. Along with the possible reasons for conflicting outcomes, considerations for ongoing and future approaches are outlined.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsLymphocyte ActivationAnti-Inflammatory AgentsAnti-HIV AgentsHumans

Stichwörter der Autor:innen

ARTHIVimmune activationimmune reconstitutioninflammation

Substanzen

Anti-Inflammatory AgentsAnti-HIV Agents

Autor:innen und Institutionen

  • Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Krystelle Nganou-Makamdop

Zitieren

APA

Nganou-Makamdop, K. (2025). Clinical and experimental treatment of residual immune activation in people living with HIV. Clinical and Experimental Immunology, 219(1). https://doi.org/10.1093/cei/uxaf023

Vancouver

Nganou-Makamdop K. Clinical and experimental treatment of residual immune activation in people living with HIV. Clinical and Experimental Immunology. 2025;219(1). doi:10.1093/cei/uxaf023

BibTeX
@article{NganouMakamdop2025,
  author = {Nganou-Makamdop, Krystelle},
  title = {Clinical and experimental treatment of residual immune activation in people living with HIV},
  journal = {Clinical and Experimental Immunology},
  year = {2025},
  volume = {219},
  number = {1},
  doi = {10.1093/cei/uxaf023}
}
Kostenlos starten →